{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:18:25Z","timestamp":1791397105487,"version":"4.3.3"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Prostate cancer remains a significant source of morbidity and mortality worldwide, with metastatic castration-sensitive disease (mCSPC) representing a complex therapeutic challenge. This review explores how a deeper understanding of the androgen receptor axis has shifted mCSPC management from monotherapy to more intense treatment. We discuss emerging data on triplet regimens, targeted therapies, and the role of local treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Randomized trials have shown that adding docetaxel or androgen receptor signaling inhibitors (ARSIs) to androgen deprivation therapy (ADT) improves survival. Triplet therapy (ADT, docetaxel, and an ARSI) improves outcomes in patients with high-volume disease compared to ADT and docetaxel alone, although comparisons to ADT plus ARSI doublet therapy are ongoing. The early use of targeted radionuclides, biomarker-driven therapies, and metastasis-directed radiotherapy has also emerged, potentially refining treatment personalization in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Current guidelines recommend ADT combined with an ARSI, with the addition of docetaxel reserved for high-volume disease. Future research aims to optimize intensity, inform biomarker-driven strategies, and reduce toxicity. Advancements in management of mCSPC underscore the importance of a multimodal, personalized approach to improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11934-025-01272-6","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T03:17:29Z","timestamp":1750475849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Packing the Punch: Current and Emerging Treatment Strategies in Metastatic Castration-Sensitive Prostate Cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Steven P.","family":"Troy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Gartrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"1272_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1272_CR2","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of Estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate**. Cancer Res. 1941;1:293\u20137.","journal-title":"Cancer Res"},{"key":"1272_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic Hormone-Sensitive prostate Cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"1272_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, Zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet"},{"key":"1272_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, De Bono JS, Spears MR, et al. Abiraterone for prostate Cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"1272_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, Castration-Sensitive prostate Cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"1272_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard First-Line therapy in metastatic prostate Cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"1272_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, Castration-Sensitive prostate Cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"1272_CR9","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, Hormone-Sensitive prostate Cancer. N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"},{"key":"1272_CR10","volume-title":"Global Cancer observatory: Cancer today","author":"J Ferlay","year":"2024","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F. Global Cancer observatory: Cancer today. France: International Agency for Research on Cancer, Lyon; 2024."},{"key":"1272_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, et al. 2022 Update on prostate Cancer epidemiology and risk Factors\u2014A systematic review. Eur Urol. 2023;84:191\u2013206.","journal-title":"Eur Urol"},{"key":"1272_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"1272_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.annonc.2023.04.515","volume":"34","author":"PA Sutera","year":"2023","unstructured":"Sutera PA, Shetty AC, Hakansson A, et al. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Ann Oncol Off J Eur Soc Med Oncol. 2023;34:605\u201314.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1272_CR14","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN. Guidelines\u00ae) for Prostate Cancer V 1.2025\u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed January 5, 2025."},{"key":"1272_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03256","author":"KS Virgo","year":"2021","unstructured":"Virgo KS, Rumble RB, de Wit R, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.20.03256.","journal-title":"J Clin Oncol"},{"key":"1272_CR16","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/cncr.21778","volume":"106","author":"KR Hess","year":"2006","unstructured":"Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer. 2006;106:1624\u201333.","journal-title":"Cancer"},{"key":"1272_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/pros.24795","volume":"85","author":"GNC De Jesus","year":"2025","unstructured":"De Jesus GNC, Pereira V, Karak P, Shearier E. A single-center retrospective review of metastatic prostate cancer on PSMA position emission tomography\/computed tomography: beyond lymph nodes and bones. Prostate. 2025;85:13\u201320.","journal-title":"Prostate"},{"key":"1272_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/pros.21420","volume":"72","author":"A Briganti","year":"2012","unstructured":"Briganti A, Suardi N, Capogrosso P, et al. Lymphatic spread of nodal metastases in high-risk prostate cancer: the ascending pathway from the pelvis to the retroperitoneum. Prostate. 2012;72:186\u201392.","journal-title":"Prostate"},{"key":"1272_CR19","volume-title":"AJCC cancer staging manual, eighth edition, corrected at 3rd printing","author":"American Joint Committee on Cancer","year":"2017","unstructured":"American Joint Committee on Cancer. AJCC cancer staging manual, eighth edition, corrected at 3rd printing. Chicago, IL: AJCC, American Joint Committee on Cancer; 2017."},{"key":"1272_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, Van Den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate Cancer. Eur Urol. 2021;79:263\u201382.","journal-title":"Eur Urol"},{"key":"1272_CR21","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A, et al. Prostate-Specific membrane antigen ligand positron emission tomography in men with nonmetastatic Castration-Resistant prostate Cancer. Clin Cancer Res. 2019;25:7448\u201354.","journal-title":"Clin Cancer Res"},{"key":"1272_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow KM, So WZ, Lee HJ, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of Intermediate- to High-risk prostate cancer: A systematic review and Meta-analysis. Eur Urol. 2023;84:36\u201348.","journal-title":"Eur Urol"},{"key":"1272_CR23","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/cncr.31173","volume":"124","author":"V Sailer","year":"2018","unstructured":"Sailer V, Schiffman MH, Kossai M, et al. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2018;124:1008\u201315.","journal-title":"Cancer"},{"key":"1272_CR24","doi-asserted-by":"crossref","unstructured":"Giri VN, Knudsen KE, Kelly WK et al. (2020) Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol 38:2798\u20132811.","DOI":"10.1200\/JCO.20.00046"},{"key":"1272_CR25","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, Buckley DI, Griffin JC, Cookson MS. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209:1082\u201390.","journal-title":"J Urol"},{"key":"1272_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-Repair gene mutations in men with metastatic prostate Cancer. N Engl J Med. 2016;375:443\u201353.","journal-title":"N Engl J Med"},{"key":"1272_CR27","doi-asserted-by":"crossref","unstructured":"Abida W, Armenia J, Gopalan A et al. (2017) Prospective genomic profiling of prostate Cancer across disease States reveals germline and somatic alterations that May affect clinical decision making. JCO Precis Oncol 1\u201316.","DOI":"10.1200\/PO.17.00029"},{"key":"1272_CR28","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J De Bono","year":"2020","unstructured":"De Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic Castration-Resistant prostate Cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"1272_CR29","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1016\/j.clgc.2017.10.025","volume":"16","author":"J Morote","year":"2018","unstructured":"Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, Ferrer R, Carles J, Regis L. Serum testosterone levels in prostate Cancer patients undergoing luteinizing hormone-Releasing hormone agonist therapy. Clin Genitourin Cancer. 2018;16:e491\u20136.","journal-title":"Clin Genitourin Cancer"},{"key":"1272_CR30","doi-asserted-by":"crossref","unstructured":"Tan YG, Poon RJ, Pang LJ, Villanueva A, Huang HH, Chen K, Ng TK, Tay KJ, Ho HS, Yuen JS. (2020) Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry. Urol Oncol Semin Orig Investig 38:682.e1-682.e9.","DOI":"10.1016\/j.urolonc.2020.05.005"},{"key":"1272_CR31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.4065\/76.12.1199","volume":"76","author":"LJ Melton","year":"2001","unstructured":"Melton LJ, Alothman KI, Achenbach SJ, O\u2019Fallon WM, Zincke H. Decline in bilateral orchiectomy for prostate Cancer in olmsted County, Minnesota, 1956\u20132000. Mayo Clin Proc. 2001;76:1199\u2013203.","journal-title":"Mayo Clin Proc"},{"key":"1272_CR32","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for Androgen-Deprivation therapy in advanced prostate Cancer. N Engl J Med. 2020;382:2187\u201396.","journal-title":"N Engl J Med"},{"key":"1272_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cancers15020461","volume":"15","author":"P Posdzich","year":"2023","unstructured":"Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B, Gr\u00fcnwald V. Metastatic prostate Cancer\u2014A review of current treatment options and promising new approaches. Cancers. 2023;15:461.","journal-title":"Cancers"},{"key":"1272_CR34","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.21873\/invivo.12355","volume":"35","author":"N Fujimoto","year":"2021","unstructured":"Fujimoto N, Shiota M, Matsukawa T, Minato A, Tomisaki I, Ohnishi R, Eto M. Three-month prostate-specific antigen level after androgen deprivation therapy predicts survival in patients with metastatic Castration-sensitive prostate Cancer. Vivo. 2021;35:1101\u20138.","journal-title":"Vivo"},{"key":"1272_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate Cancer. JNCI J Natl Cancer Inst. 2010;102:39\u201346.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1272_CR36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SMH, Basaria S, D\u2019Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825\u201336.","journal-title":"Eur Urol"},{"key":"1272_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","volume":"11","author":"J Irani","year":"2010","unstructured":"Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of Venlafaxine, Medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010;11:147\u201354.","journal-title":"Lancet Oncol"},{"key":"1272_CR38","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.urology.2010.03.033","volume":"76","author":"TM Beer","year":"2010","unstructured":"Beer TM, Benavides M, Emmons SL, Hayes M, Liu G, Garzotto M, Donovan D, Katovic N, Reeder C, Eilers K. Acupuncture for hot flashes in patients with prostate Cancer. Urology. 2010;76:1182\u20138.","journal-title":"Urology"},{"key":"1272_CR39","first-page":"62","volume":"38","author":"P Cormie","year":"2020","unstructured":"Cormie P, Zopf EM. Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer. Urol Oncol Semin Orig Investig. 2020;38:62\u201370.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"1272_CR40","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men receiving Androgen-Deprivation therapy for prostate Cancer. N Engl J Med. 2009;361:745\u201355.","journal-title":"N Engl J Med"},{"key":"1272_CR41","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR. Randomized controlled trial of annual Zoledronic acid to prevent Gonadotropin-Releasing hormone Agonist\u2013Induced bone loss in men with prostate Cancer. J Clin Oncol. 2007;25:1038\u201342.","journal-title":"J Clin Oncol"},{"key":"1272_CR42","doi-asserted-by":"publisher","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of Once-Weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trial. Ann Intern Med. 2007;146:416.","journal-title":"Ann Intern Med"},{"key":"1272_CR43","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.euf.2019.11.010","volume":"6","author":"JP Izard","year":"2020","unstructured":"Izard JP, Siemens DR. Androgen deprivation therapy and mental health: impact on depression and cognition. Eur Urol Focus. 2020;6:1162\u20134.","journal-title":"Eur Urol Focus"},{"key":"1272_CR44","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.6004\/jnccn.2015.0109","volume":"13","author":"VK Pokuri","year":"2015","unstructured":"Pokuri VK, Nourkeyhani H, Betsy B, Herbst L, Sikorski M, Spangenthal E, Fabiano A, George S. Strategies to circumvent testosterone surge and disease flare in advanced prostate cancer: emerging treatment paradigms. J Natl Compr Canc Netw. 2015;13:e49\u201355.","journal-title":"J Natl Compr Canc Netw"},{"key":"1272_CR45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S0022-5347(17)39625-8","volume":"144","author":"H Schulze","year":"1990","unstructured":"Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing hormone-Releasing hormone Analogue-Induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol. 1990;144:934\u201341.","journal-title":"J Urol"},{"key":"1272_CR46","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S0022-5347(17)43380-5","volume":"138","author":"F Labrie","year":"1987","unstructured":"Labrie F, Dupont A, Belanger A, Lachance R. Flutamide eliminates the risk of disease flare in prostatic Cancer patients treated with a luteinizing hormone-Releasing hormone agonist. J Urol. 1987;138:804\u20136.","journal-title":"J Urol"},{"key":"1272_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2147\/CIA.S1395","volume":"2","author":"VJ Sinibaldi","year":"2008","unstructured":"Sinibaldi VJ. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. Clin Interv Aging Volume. 2008;2:555\u201360.","journal-title":"Clin Interv Aging Volume"},{"key":"1272_CR48","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate Cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"1272_CR49","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.clon.2008.07.002","volume":"20","author":"ND James","year":"2008","unstructured":"James ND, Sydes MR, Clarke NW, et al. STAMPEDE: systemic therapy for advancing or metastatic prostate Cancer \u2014 A Multi-Arm Multi-Stage randomised controlled trial. Clin Oncol. 2008;20:577\u201381.","journal-title":"Clin Oncol"},{"key":"1272_CR50","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30:1992\u20132003.","journal-title":"Ann Oncol"},{"key":"1272_CR51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149\u201358.","journal-title":"Lancet Oncol"},{"key":"1272_CR52","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher J-M, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic Non castrate prostate cancer: impact of metastatic burden and Long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70:256\u201362.","journal-title":"Eur Urol"},{"key":"1272_CR53","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","volume":"73","author":"G Gravis","year":"2018","unstructured":"Gravis G, Boher J-M, Chen Y-H, et al. Burden of metastatic castrate Naive prostate Cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol. 2018;73:847\u201355.","journal-title":"Eur Urol"},{"key":"1272_CR54","doi-asserted-by":"crossref","unstructured":"Gillessen S, Attard G, Beer TM et al. (2020) Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 77:508\u2013547.","DOI":"10.1016\/j.eururo.2020.01.012"},{"key":"1272_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/CAD.0000000000000428","volume":"28","author":"C Della Pepa","year":"2017","unstructured":"Della Pepa C, Cavaliere C, Rossetti S, et al. Predictive comprehensive geriatric assessment in elderly prostate cancer patients: the prospective observational scoop trial results. Anticancer Drugs. 2017;28:104\u20139.","journal-title":"Anticancer Drugs"},{"key":"1272_CR56","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.23.00723","volume":"41","author":"J Wala","year":"2023","unstructured":"Wala J, Nguyen P, Pomerantz M. Early treatment intensification in metastatic Hormone-Sensitive prostate Cancer. J Clin Oncol. 2023;41:3584\u201390.","journal-title":"J Clin Oncol"},{"key":"1272_CR57","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with Androgen-Deprivation therapy in patients with metastatic Hormone-Sensitive prostate Cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42:4271\u201381.","journal-title":"J Clin Oncol"},{"key":"1272_CR58","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate Cancer. Endocr Rev. 2021;42:354\u201373.","journal-title":"Endocr Rev"},{"key":"1272_CR59","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS De Bono","year":"2011","unstructured":"De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate Cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"1272_CR60","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","volume":"69","author":"G Attard","year":"2009","unstructured":"Attard G, Reid AHM, Olmos D, De Bono JS. Antitumor activity with CYP17 Blockade indicates that Castration-Resistant prostate Cancer frequently remains hormone driven. Cancer Res. 2009;69:4937\u201340.","journal-title":"Cancer Res"},{"key":"1272_CR61","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700.","journal-title":"Lancet Oncol"},{"key":"1272_CR62","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","volume":"24","author":"G Attard","year":"2023","unstructured":"Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol. 2023;24:443\u201356.","journal-title":"Lancet Oncol"},{"key":"1272_CR63","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"key":"1272_CR64","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14740338.2019.1648428","volume":"18","author":"P Castellan","year":"2019","unstructured":"Castellan P, Castellucci R, Marchioni M, De Nunzio C, Tema G, Primiceri G, Schips L, Cindolo L. A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer. Expert Opin Drug Saf. 2019;18:759\u201367.","journal-title":"Expert Opin Drug Saf"},{"key":"1272_CR65","unstructured":"Janssen Biotech, Inc. Abiraterone acetate (Zytiga) [package insert]. FDALabel Database; 2024."},{"key":"1272_CR66","doi-asserted-by":"crossref","unstructured":"Goryachok M, Nicklawsky A, Ahmad H, Geiger C, Kim S, Flaig TW. (2024) Effect of prednisone dosing on Mineralocorticoid-Related side effects with abiraterone in prostate Cancer. JCO Oncol Pract OP-24-00472.","DOI":"10.1200\/JCO.2024.42.4_suppl.67"},{"key":"1272_CR67","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2016.02.035","volume":"70","author":"K Fizazi","year":"2016","unstructured":"Fizazi K, Chi KN, De Bono JS, et al. Low incidence of Corticosteroid-associated adverse events on Long-term exposure to Low-dose prednisone given with abiraterone acetate to patients with metastatic Castration-resistant prostate Cancer. Eur Urol. 2016;70:438\u201344.","journal-title":"Eur Urol"},{"key":"1272_CR68","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41391-023-00757-0","volume":"27","author":"YHA Lee","year":"2024","unstructured":"Lee YHA, Hui JMH, Leung CH, et al. Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostatic Dis. 2024;27:776\u201382.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1272_CR69","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","volume":"77","author":"G Lu-Yao","year":"2020","unstructured":"Lu-Yao G, Nikita N, Keith SW, et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate Cancer by Pre-existing cardiovascular comorbidities. Eur Urol. 2020;77:158\u201366.","journal-title":"Eur Urol"},{"key":"1272_CR70","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/jnci\/djac081","volume":"114","author":"LY Lai","year":"2022","unstructured":"Lai LY, Oerline MK, Caram MEV, Tsao PA, Kaufman SR, Hollenbeck BK, Shahinian VB. Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate Cancer. JNCI J Natl Cancer Inst. 2022;114:1127\u201334.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1272_CR71","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate Cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"1272_CR72","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic Hormone-Sensitive prostate Cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"1272_CR73","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic Hormone-Sensitive prostate Cancer. J Clin Oncol. 2022;40:1616\u201322.","journal-title":"J Clin Oncol"},{"key":"1272_CR74","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41391-022-00541-6","volume":"26","author":"LG Briggs","year":"2023","unstructured":"Briggs LG, Reese S, Herzog P, Nguyen D-D, Labban M, Alkhatib K, Trinh Q-D, Morgans AK. Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors\u2009\u00b1\u2009androgen deprivation therapy: a pharmacovigilance study. Prostate Cancer Prostatic Dis. 2023;26:331\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1272_CR75","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40264-024-01415-7","volume":"47","author":"BW Lennep","year":"2024","unstructured":"Lennep BW, Mack J, Poondru S, Hood E, Looney BD, Williams M, Bianco JJ, Morgans AK. Enzalutamide: Understanding and managing drug interactions to improve patient safety and drug efficacy. Drug Saf. 2024;47:617\u201341.","journal-title":"Drug Saf"},{"key":"1272_CR76","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate Cancer. Eur Urol. 2021;79:150\u20138.","journal-title":"Eur Urol"},{"key":"1272_CR77","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic Castration-Sensitive prostate cancer: final survival analysis of the randomized, Double-Blind, phase III TITAN study. J Clin Oncol. 2021;39:2294\u2013303.","journal-title":"J Clin Oncol"},{"key":"1272_CR78","unstructured":"Janssen Biotech, Inc. Apalutamide (Erleada) [package insert]. FDALabel Database; 2024."},{"key":"1272_CR79","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40487-024-00290-7","volume":"12","author":"AJ Birtle","year":"2024","unstructured":"Birtle AJ, Formisano L, Descamps V, Weisenseel P, Vilaseca A. Early identification and management of patients with rash on apalutamide. Oncol Ther. 2024;12:609\u201320.","journal-title":"Oncol Ther"},{"key":"1272_CR80","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s10147-020-01777-9","volume":"25","author":"K Mori","year":"2020","unstructured":"Mori K, Mostafaei H, Pradere B, et al. Apalutamide, Enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020;25:1892\u2013900.","journal-title":"Int J Clin Oncol"},{"key":"1272_CR81","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41391-021-00395-4","volume":"25","author":"M Wenzel","year":"2022","unstructured":"Wenzel M, Nocera L, Coll\u00e0 Ruvolo C, et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis. 2022;25:139\u201348.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1272_CR82","doi-asserted-by":"publisher","first-page":"1131033","DOI":"10.3389\/fendo.2023.1131033","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang G, Wang J, Bi J. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis. Front Endocrinol. 2023;14:1131033.","journal-title":"Front Endocrinol"},{"key":"1272_CR83","unstructured":"Bayer Healthcare Pharmaceuticals Inc. Darolutamide (Nubeqa) [package insert]. FDALabel Database; 2023."},{"key":"1272_CR84","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40262-023-01268-w","volume":"62","author":"E Podgor\u0161ek","year":"2023","unstructured":"Podgor\u0161ek E, Mehra N, Van Oort IM, Somford DM, Boerrigter E, Van Erp NP. Clinical pharmacokinetics and pharmacodynamics of the next generation androgen receptor Inhibitor\u2014Darolutamide. Clin Pharmacokinet. 2023;62:1049\u201361.","journal-title":"Clin Pharmacokinet"},{"key":"1272_CR85","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399:1695\u2013707.","journal-title":"Lancet"},{"key":"1272_CR86","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","volume":"9","author":"P Mandel","year":"2023","unstructured":"Mandel P, Hoeh B, Wenzel M, Preisser F, Tian Z, Tilki D, Steuber T, Karakiewicz PI, Chun FKH. Triplet or doublet therapy in metastatic Hormone-sensitive prostate Cancer patients: A systematic review and network Meta-analysis. Eur Urol Focus. 2023;9:96\u2013105.","journal-title":"Eur Urol Focus"},{"key":"1272_CR87","unstructured":"Fenton S. (2024) Randomized Phase II Study of ADT\u2009+\u2009Abiraterone vs ADT\u2009+\u2009Docetaxel\u2009+\u2009Abiraterone. ClinicalTrials.gov."},{"key":"1272_CR88","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13014-022-02004-7","volume":"17","author":"D Correia","year":"2022","unstructured":"Correia D, Moullet B, Cullmann J, Heiss R, Ermi\u015f E, Aebersold DM, Hemmatazad H. Response assessment after stereotactic body radiation therapy for spine and non-spine bone metastases: results from a single institutional study. Radiat Oncol. 2022;17:37.","journal-title":"Radiat Oncol"},{"key":"1272_CR89","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.semradonc.2021.03.007","volume":"31","author":"MP Deek","year":"2021","unstructured":"Deek MP, Phillips RM, Tran PT. Local therapies in oligometastatic & oligoprogressive prostate Cancer. Semin Radiat Oncol. 2021;31:242\u20139.","journal-title":"Semin Radiat Oncol"},{"key":"1272_CR90","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353\u201366.","journal-title":"Lancet"},{"key":"1272_CR91","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","volume":"7","author":"A Ali","year":"2021","unstructured":"Ali A, Hoyle A, Haran \u00c1M, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol. 2021;7:555.","journal-title":"JAMA Oncol"},{"key":"1272_CR92","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","volume":"404","author":"A Bossi","year":"2024","unstructured":"Bossi A, Foulon S, Maldonado X, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2024;404:2065\u201376.","journal-title":"Lancet"},{"key":"1272_CR93","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"Boev\u00e9 LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar RJAV, Verhagen PCMS, Van Andel G. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate Cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75:410\u20138.","journal-title":"Eur Urol"},{"key":"1272_CR94","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"Burdett S, Boev\u00e9 LM, Ingleby FC, et al. Prostate radiotherapy for metastatic Hormone-sensitive prostate cancer: A STOPCAP systematic review and Meta-analysis. Eur Urol. 2019;76:115\u201324.","journal-title":"Eur Urol"},{"key":"1272_CR95","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bju.15669","volume":"130","author":"P Sooriakumaran","year":"2022","unstructured":"Sooriakumaran P, Wilson C, Rombach I, et al. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the testing radical prostatectomy in men with prostate cancer and oligo\u2010Metastases to the bone (TRoMbone) trial. BJU Int. 2022;130:43\u201353.","journal-title":"BJU Int"},{"key":"1272_CR96","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","volume":"10","author":"M Hussain","year":"2024","unstructured":"Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, Saad F. Metastatic Hormone-Sensitive prostate Cancer and combination treatment outcomes: A review. JAMA Oncol. 2024;10:807.","journal-title":"JAMA Oncol"},{"key":"1272_CR97","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, et al. DNA-Repair defects and Olaparib in metastatic prostate Cancer. N Engl J Med. 2015;373:1697\u2013708.","journal-title":"N Engl J Med"},{"key":"1272_CR98","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162\u201374.","journal-title":"Lancet Oncol"},{"key":"1272_CR99","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.3390\/curroncol29070400","volume":"29","author":"JE Deluce","year":"2022","unstructured":"Deluce JE, Cardenas L, Lalani A-K, Maleki Vareki S, Fernandes R. Emerging Biomarker-Guided therapies in prostate Cancer. Curr Oncol. 2022;29:5054\u201376.","journal-title":"Curr Oncol"},{"key":"1272_CR100","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","volume":"84","author":"W Abida","year":"2023","unstructured":"Abida W, Campbell D, Patnaik A, et al. Rucaparib for the treatment of metastatic Castration-resistant prostate Cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. Eur Urol. 2023;84:321\u201330.","journal-title":"Eur Urol"},{"key":"1272_CR101","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/gcc.22903","volume":"60","author":"C Nientiedt","year":"2021","unstructured":"Nientiedt C, Duensing A, Zsch\u00e4bitz S, J\u00e4ger D, Hohenfellner M, Stenzinger A, Duensing S. PARP Inhibition in prostate cancer. Genes Chromosomes Cancer. 2021;60:344\u201351.","journal-title":"Genes Chromosomes Cancer"},{"key":"1272_CR102","doi-asserted-by":"publisher","first-page":"TPS5123","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5123","volume":"42","author":"KN Chi","year":"2024","unstructured":"Chi KN, Agarwal N, Armstrong AJ, et al. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of Saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). J Clin Oncol. 2024;42:TPS5123\u20135123.","journal-title":"J Clin Oncol"},{"key":"1272_CR103","doi-asserted-by":"publisher","first-page":"TPS176","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS176","volume":"39","author":"DE Rathkopf","year":"2021","unstructured":"Rathkopf DE, Chi KN, Olmos D, et al. AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). J Clin Oncol. 2021;39:TPS176\u2013176.","journal-title":"J Clin Oncol"},{"key":"1272_CR104","doi-asserted-by":"publisher","first-page":"13519","DOI":"10.3390\/ijms222413519","volume":"22","author":"V Mollica","year":"2021","unstructured":"Mollica V, Marchetti A, Rosellini M, Nuvola G, Rizzo A, Santoni M, Cimadamore A, Montironi R, Massari F. An insight on novel molecular pathways in metastatic prostate cancer: A focus on DDR, MSI and AKT. Int J Mol Sci. 2021;22:13519.","journal-title":"Int J Mol Sci"},{"key":"1272_CR105","doi-asserted-by":"crossref","unstructured":"Fizazi K, George DJ, De Santis M, et al. A phase III trial of Capivasertib and abiraterone versus placebo and abiraterone in patients with de Novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281). J Clin Oncol. 2021;39:TPS178\u2013178.","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS178"},{"key":"1272_CR106","unstructured":"Kemp A. (2024) Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 phase III trial."},{"key":"1272_CR107","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, et al. Surveillance or Metastasis-Directed therapy for oligometastatic prostate Cancer recurrence: A prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446\u201353.","journal-title":"J Clin Oncol"},{"key":"1272_CR108","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650.","journal-title":"JAMA Oncol"},{"key":"1272_CR109","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van Der Eecken K, Sutera P, et al. Long-Term outcomes and genetic predictors of response to Metastasis-Directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40:3377\u201382.","journal-title":"J Clin Oncol"},{"key":"1272_CR110","unstructured":"Jereczek-Fossa BA, Borghesi S, Marvaso G, Mastroleo F, Ost P, Tang C. Understanding the disruptive potential of MDT in metastatic prostate Cancer treatment. Exploring Hypotheses for Future Studies. ASCO Dly. News; 2025."},{"key":"1272_CR111","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1186\/s12885-022-10374-0","volume":"22","author":"K Rans","year":"2022","unstructured":"Rans K, Charlien B, Filip A, et al. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival? BMC Cancer. 2022;22:1294.","journal-title":"BMC Cancer"},{"key":"1272_CR112","first-page":"241","volume":"59","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Banerjee SR, Mease RC, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc of. 2015;59:241\u201368.","journal-title":"Q J Nucl Med Mol Imaging off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc of"},{"key":"1272_CR113","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, De Bono J, Chi KN, et al. Lutetium-177\u2013PSMA-617 for metastatic Castration-Resistant prostate Cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"1272_CR114","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus Cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"1272_CR115","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, Bressel M, Tan H, et al. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2024;25:1267\u201376.","journal-title":"Lancet Oncol"},{"key":"1272_CR116","doi-asserted-by":"crossref","unstructured":"Tagawa ST, Sartor AO, Saad F, Reid AH, Sakharova OV, Feng FY, Fizazi K, Morris MJ. PSMAddition: A phase 3 trial to compare treatment with177 Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2023;41:TPS5116\u20135116.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116"},{"key":"1272_CR117","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate Cancer. N Engl J Med. 2013;368:1314\u201325.","journal-title":"N Engl J Med"},{"key":"1272_CR118","doi-asserted-by":"crossref","unstructured":"Chong B, Saad M, Chong TW et al. (2025) Selective treatment de-escalation in advanced prostate cancer: have we come full circle? BJU Int bju.16632.","DOI":"10.1111\/bju.16632"},{"key":"1272_CR119","doi-asserted-by":"publisher","first-page":"TPS5118","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5118","volume":"42","author":"AD Choudhury","year":"2024","unstructured":"Choudhury AD, Heller G, Reimers MA, et al. A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM\/Alliance A032101). J Clin Oncol. 2024;42:TPS5118\u20135118.","journal-title":"J Clin Oncol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01272-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-025-01272-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01272-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:16:50Z","timestamp":1781608610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-025-01272-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1272"],"URL":"https:\/\/doi.org\/10.1007\/s11934-025-01272-6","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"25 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"50"}}